Dr. Agarwal’s Eye Hospital amalgamation with Dr. Agarwal’s Health Care becomes effective
● November 17, 2026 is the record date for eligible AEHL shareholders to receive 23 AHCL shares for every 2 AEHL shares held
● Amalgamation consolidates the two listed entities into a unified corporate structure
● Illustrative merger-arbitrage differential of ~5.5% at assumed market prices, before costs, taxes and market movements
Chennai, November 17, 2026: Dr. Agarwal’s Health Care Limited (NSE: AGARWALEYE, BSE: 544350) announced that the Scheme of Amalgamation of Dr. Agarwal’s Eye Hospital Limited (AEHL) with Dr. Agarwal’s Health Care Limited (AHCL) has become effective and operative from November 1, 2026.
The Hon’ble National Company Law Tribunal, Chennai Bench, sanctioned the Scheme through its order dated September 30, 2026. Following the filing of the certified NCLT order with the Registrar of Companies, Chennai, the conditions specified under the Scheme were satisfied, enabling the amalgamation to take effect.
The amalgamation brings the two listed entities together within Dr. Agarwal’s Health Care Limited, simplifying the Group’s corporate structure as it continues to expand its eye-care network. The combined structure provides a more unified framework for governance, capital allocation and long-term business planning.
The consolidation is intended to support closer alignment across investments in hospitals, clinical capabilities, technology and talent, while providing shareholders and investors with a clearer view of the combined organisation.
Commenting on the amalgamation, Dr. Adil Agarwal, CEO, Dr. Agarwal’s Health Care Limited said, “The amalgamation is an important step in simplifying our corporate structure and bringing the business together under one listed platform. As we continue to expand, a unified structure gives us a clearer framework to deploy capital, strengthen clinical capabilities and build the organisation for its next phase of growth.
Our focus remains on creating long-term value through disciplined expansion, stronger operating performance and continued investment in clinical excellence. We believe the combined structure will support greater organisational alignment as we scale across markets.”
The Board has fixed Wednesday, November 18, 2026 as the record date for determining eligible shareholders of Dr. Agarwal’s Eye Hospital Limited who will receive shares of Dr. Agarwal’s Health Care Limited pursuant to the Scheme.
Under the approved share exchange ratio, eligible AEHL shareholders will receive 23 fully paid-up equity shares of AHCL of face value ₹1 each for every 2 fully paid-up equity shares of AEHL of face value ₹10 each held. This is equivalent to 11.5 AHCL shares for every one AEHL share.
How the exchange ratio translates at illustrative market prices
For illustration, at an AEHL share price of approximately ₹6,000, the 11.5-share exchange ratio implies an effective acquisition cost of approximately ₹522 per AHCL share (₹6,000 ÷ 11.5).
Against an illustrative AHCL market price of approximately ₹550 per share, this represents a gross price differential of around ₹28–30 per AHCL share, or approximately 5.5%, before transaction costs, taxes, statutory charges and any movement in the market prices of the two securities.
The above calculation is illustrative and is intended only to explain the mathematical effect of the approved exchange ratio at the assumed prices. Actual market prices and the resulting differential may vary. Nothing in this release constitutes investment advice, a recommendation to buy or sell securities, or an assurance of return.
About Dr. Agarwal’s Health Care Limited
Dr. Agarwal’s Health Care Limited, a trusted brand in the eye care services industry and according to Crisil Intelligence, is India’s largest eye care service chain by revenue from operations for FY25. With long-standing operational history, we endeavour to address all the needs of our patients in their eye treatment journey through a network of 305 facilities across 14 states and 5 UTs in India and 19 facilities across Africa. The Company has a diversified presence, with 103 facilities located in tier-I cities and 202 facilities in other cities across India.
We provide end-to-end comprehensive eye care services, including cataract, refractive and other surgeries; consultations, diagnoses and non-surgical treatments; and sell opticals, contact lenses and accessories, and eye care related pharmaceutical products. Our business operations are structured as a “hub and spoke” model, which enables us to build a scalable and accessible platform for the continued growth of our business.
Our integrated hub-and-spoke model enables deeper geographic penetration, allowing greater accessibility to patients while driving efficiency of critical resources across the network.

